Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.74 |
| ▸ | FLT3 | P36888 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776474 | 0.89 | MET (0.74) | METFLT3KDR | |
| SCHEMBL4774270 | 0.88 | MET (0.58) | METFLT3 | |
| SCHEMBL4819452 | 0.87 | MET (0.75) | METFLT3 | |
| SCHEMBL4775389 | 0.87 | MET (0.71) | METFLT3KDR | |
| SCHEMBL4774249 | 0.86 | MET (0.67) | METFLT3KDR | |
| SCHEMBL4772466 | 0.86 | MET (0.80) | METFLT3KDR | |
| SCHEMBL8288992 | 0.86 | MET (0.67) | METFLT3KDR | |
| SCHEMBL14028170 | 0.86 | MET (0.67) | METFLT3KDR | |
| SCHEMBL4068304 | 0.86 | MET (0.83) | METFLT3KDR | |
| SCHEMBL4820020 | 0.86 | MET (0.86) | METFLT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| EP-1751153-B1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1709043-B1 | PYRROLOPYRIDINE-SUBSTITUTED BENZOL DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1709043-B1 | PYRROLOPYRIDINE-SUBSTITUTED BENZOL DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1751153-B1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080249105-A1 | Pyrrolopyridine-Substituted Benzol Derivatives for Treating Cardiovascular Diseases | BAYER HEALTHCARE AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249105-A1 | Pyrrolopyridine-Substituted Benzol Derivatives for Treating Cardiovascular Diseases | BAYER HEALTHCARE AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| EP-1709043-A1 | PYRROLOPYRIDINE-SUBSTITUTED BENZOL DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005097790-A1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005058891-A1 | PYRROLOPYRIDINE-SUBSTITUTED BENZOL DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058891-A1 | PYRROLOPYRIDINE-SUBSTITUTED BENZOL DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249105-A1 | Pyrrolopyridine-Substituted Benzol Derivatives for Treating Cardiovascular Diseases | PHB2, PHB1, TNNT2 | MET 4445/4885FLT3 1688/4885KDR 1284/4885 |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | TNK2, ROCK1, ROCK2 | MET 1524/4885FLT3 867/4885KDR 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.